Imagine what will happen when the market realises it's been in 1,500 patients with bucket loads of positive data, was previously approved to treat a very difficult to treat blood cancer, has been pretty much the only drug to work on EMD AML.
Based on treating AML alone, we should have a MC of $1 billion.
The new plan is now to improve the SOC for patients receiving the most widely prescribed anti cancer drug in the world. If it improves the SOC by only 10%, clinicians will use it. We are now heading into unchartered territory for an Aussie biotech:
1. Extended blackout period, why? 2. MOA is known, not being released to protect IP. 3. IN THE ARMS OF AT LEAST ONE PATIENT, WITH NO KNOWN ISSUES. 4. Tightly held register, once an ex director is out, it will be even tighter. 5. No. 1 holder and CEO will only do a deal that will benefit all SH, not just him.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)